CB(1) cannabinoid receptors and their associated proteins
- PMID: 20166926
- PMCID: PMC3179980
- DOI: 10.2174/092986710790980023
CB(1) cannabinoid receptors and their associated proteins
Abstract
CB1 receptors are G-protein coupled receptors (GPCRs) abundant in neurons, in which they modulate neurotransmission. The CB(1) receptor influence on memory and learning is well recognized, and disease states associated with CB(1) receptors are observed in addiction disorders, motor dysfunction, schizophrenia, and in bipolar, depression, and anxiety disorders. Beyond the brain, CB(1) receptors also function in liver and adipose tissues, vascular as well as cardiac tissue, reproductive tissues and bone. Signal transduction by CB(1) receptors occurs through interaction with Gi/o proteins to inhibit adenylyl cyclase, activate mitogen-activated protein kinases (MAPK), inhibit voltage-gated Ca(2+) channels, activate K(+) currents (K(ir)), and influence Nitric Oxide (NO) signaling. CB(1) receptors are observed in internal organelles as well as plasma membrane. beta-Arrestins, adaptor protein AP-3, and G-protein receptor-associated sorting protein 1 (GASP1) modulate cellular trafficking. Cannabinoid Receptor Interacting Protein1a (CRIP1a) is an accessory protein whose function has not been delineated. Factor Associated with Neutral sphingomyelinase (FAN) regulates ceramide signaling. Such diversity in cellular signaling and modulation by interacting proteins suggests that agonists and allosteric modulators could be developed to specifically regulate unique, cell type-specific responses.
Conflict of interest statement
Conflict of Interest: The authors have not received financial contributions to the work being reported, and do not report any conflict of interest. ACH has served on the speaker’s bureau for Sanofi-Aventis within the last three years.
References
-
- Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 1990;13:420–423. - PubMed
-
- Johnson MR, Melvin LS, Althuis TH, Bindra JS, Harbert CA, Milne GM, Weissman A. Selective and potent analgetics derived from cannabinoids. J Clin Pharmacol. 1981;21:271S–282S. - PubMed
-
- Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006;7:25–29. - PubMed
-
- Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 1981;21:320S–326S. - PubMed
-
- Young AM, Katz JL, Woods JH. Behavioral effects of levonantradol and nantradol in the rhesus monkey. J Clin Pharmacol. 1981;21:348S–360S. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous